- Home
- NPKI vs PLRX Comparison
NPKI vs PLRX Comparison
Compare NPKI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- PLRX
- Stock Information
- Founded
- NPKI 1932
- PLRX 2015
- Country
- NPKI United States
- PLRX United States
- Employees
- NPKI N/A
- PLRX N/A
- Industry
- NPKI Metal Fabrications
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- PLRX Health Care
- Exchange
- NPKI Nasdaq
- PLRX Nasdaq
- Market Cap
- NPKI 665.2M
- PLRX 682.2M
- IPO Year
- NPKI N/A
- PLRX 2020
- Fundamental
- Price
- NPKI $7.67
- PLRX $10.92
- Analyst Decision
- NPKI
- PLRX Strong Buy
- Analyst Count
- NPKI 0
- PLRX 7
- Target Price
- NPKI N/A
- PLRX $40.50
- AVG Volume (30 Days)
- NPKI 376.9K
- PLRX 454.1K
- Earning Date
- NPKI 02-19-2025
- PLRX 02-26-2025
- Dividend Yield
- NPKI N/A
- PLRX N/A
- EPS Growth
- NPKI N/A
- PLRX N/A
- EPS
- NPKI N/A
- PLRX N/A
- Revenue
- NPKI $748,372,000.00
- PLRX N/A
- Revenue This Year
- NPKI N/A
- PLRX N/A
- Revenue Next Year
- NPKI N/A
- PLRX N/A
- P/E Ratio
- NPKI N/A
- PLRX N/A
- Revenue Growth
- NPKI 93.70
- PLRX N/A
- 52 Week Low
- NPKI $5.61
- PLRX $10.22
- 52 Week High
- NPKI $8.65
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- PLRX 36.45
- Support Level
- NPKI N/A
- PLRX $10.68
- Resistance Level
- NPKI N/A
- PLRX $11.40
- Average True Range (ATR)
- NPKI 0.00
- PLRX 0.71
- MACD
- NPKI 0.00
- PLRX -0.14
- Stochastic Oscillator
- NPKI 0.00
- PLRX 7.92
About NPKI NPK International Inc. Common Stock
NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.